This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to investigate the potential role of the reactive glycolytic byproduct methylglyoxal (MG) in triggering early-onset neurological disorders in people living with HIV (PLWH). The $652,375 award, valid from August 15, 2024 to June 30, 2026, aims to: 1) Define the pathobiological trajectory of neurological disorders in relation to MG, microvascular leakage, and inflammation in HIV-infected humanized mouse models, with and without antiretroviral treatment, and 2) Evaluate the ability of novel arginine-rich cyclic peptides to lower MG levels and mitigate neurological disorders in the same mouse models. This research seeks to establish a link between elevated MG, microvascular dysfunction, and neurological complications in PLWH, while also providing insights into the potential therapeutic use of the peptides to manage these disorders.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $191.9k | 6/11/25 | ||
| Not listed | $230.3k | 8/6/24 | ||
| Not listed | $230.3k | 8/6/24 |